IMHO any valuation needs to be made on the basis of an estimation of cashflows over the med-long term (this applies to every stock). In CHM's case, you can't use the metrics you quoted as a basis for projecting cashflows. Read any analyst report on any early stage biotech and you will see what methods they use to predict these cashflows - they don't involve those metrics.
My analysis and intrinsic value of CHM March 2022, page-13
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $11.72K | 2.783M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 2757364 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 15260220 | 25 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |